CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma
- PMID: 17255259
- DOI: 10.1158/1078-0432.CCR-06-1734
CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma
Abstract
Purpose: Follicular lymphoma is a heterogeneous disease with variable prognosis and clinical course. We hypothesized that the presence of nonmalignant T cells in the microenvironment of the tumor may affect the outcome.
Experimental design: Using flow cytometry, we evaluated the T-cell subsets in the lymph node microenvironment of follicular lymphoma. All patients in South Stockholm County with indolent follicular lymphoma and with flow cytometry done on a diagnostic lymph node between 1994 and 2004 were included (N = 139). Diagnosis and grade (1, 2, and 3a) were confirmed by re-review. Flow cytometry results were reanalyzed. Lymphocyte subsets, the Follicular Lymphoma International Prognostic Index, grade, and clinical characteristics were evaluated in univariable and multivariable Cox analysis with respect to overall survival (OS) and disease-specific survival (DSS).
Results: Higher CD8+ T-cell levels correlated with longer OS and DSS, independently of the Follicular Lymphoma International Prognostic Index (OS, P = 0.017; DSS, P = 0.020) and independently of all other prognostic factors (OS, P = 0.001; DSS, P = 0.004). Median OS was not reached for patients in the upper quarter of CD8+ T-cell levels (>8.6%), 10.4 years for patients in the middle half (4.2-8.6%), and 6.0 years for patients in the lower quarter (<4.2%). Furthermore, patients who had not required treatment within 6 months from diagnosis had more CD8+ T cells (P = 0.011).
Conclusions: Higher levels of CD8+ T cells predict a better prognosis, and these data support an important role for nonmalignant immune cells in the biology of follicular lymphoma. Evaluating the CD8+ T cells by flow cytometry at diagnosis may provide prognostic information.
Similar articles
-
A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.Clin Cancer Res. 2010 Jan 15;16(2):637-50. doi: 10.1158/1078-0432.CCR-09-2487. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068089
-
Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.Hum Pathol. 2011 Apr;42(4):552-7. doi: 10.1016/j.humpath.2010.08.015. Epub 2011 Jan 15. Hum Pathol. 2011. PMID: 21237493
-
Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.Eur J Haematol. 2008 Oct;81(4):289-97. doi: 10.1111/j.1600-0609.2008.01113.x. Epub 2008 Jul 8. Eur J Haematol. 2008. PMID: 18616513
-
Leukemic phase of mantle cell lymphoma two case reports and review of the literature.Arch Pathol Lab Med. 1996 Jan;120(1):35-40. Arch Pathol Lab Med. 1996. PMID: 8554442 Review.
-
Follicular variant of peripheral T-cell lymphoma mimicking follicular lymphoma: a case report with a review of the Literature.Pathol Int. 2011 May;61(5):326-30. doi: 10.1111/j.1440-1827.2011.02656.x. Epub 2011 Mar 30. Pathol Int. 2011. PMID: 21501301 Review.
Cited by
-
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.Haematologica. 2009 Jan;94(1):70-7. doi: 10.3324/haematol.13574. Epub 2008 Dec 4. Haematologica. 2009. PMID: 19059937 Free PMC article.
-
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z. Biomark Res. 2024. PMID: 39020411 Free PMC article. Review.
-
High inter-follicular spatial co-localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma.Hematol Oncol. 2022 Oct;40(4):541-553. doi: 10.1002/hon.3003. Epub 2022 Apr 28. Hematol Oncol. 2022. PMID: 35451108 Free PMC article.
-
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody.Immune Netw. 2022 Feb 14;22(1):e4. doi: 10.4110/in.2022.22.e4. eCollection 2022 Feb. Immune Netw. 2022. PMID: 35291652 Free PMC article. Review.
-
SIRPα expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma.Blood Cancer J. 2019 Oct 14;9(10):84. doi: 10.1038/s41408-019-0246-0. Blood Cancer J. 2019. PMID: 31611550 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials